{"product_id":"klow80-bpc-157-10mg-ghk-cu-50mg-tb-500-10mg-kpv-10mg","title":"KLOW80 (BPC-157 10mg + GHK-CU 50mg + TB-500 10mg + KPV 10mg)","description":"\u003cp\u003e\u003cstrong\u003eBuy high-purity KLOW80 stack in Australia (BPC-157 10mg + GHK-Cu 50mg + TB-500 10mg + KPV 10mg, 80mg total). Third-party lab tested at \u0026gt;99% purity. Australian-domestic shipping, AUD pricing, supplied for laboratory research use only.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003ch2\u003eAbout the KLOW80 stack\u003c\/h2\u003e\n\u003cp\u003eKLOW80 is a four-compound research stack co-lyophilised in a single vial: 10mg BPC-157 (a pentadecapeptide derived from gastric juice protein BPC), 50mg GHK-Cu (a copper-binding tripeptide), 10mg TB-500 (a 17-amino-acid fragment of thymosin β-4), and 10mg KPV (an α-MSH-derived tripeptide, Lys-Pro-Val). KLOW80 extends the GLOW70 stack with KPV's anti-inflammatory and gut-barrier research profile, giving researchers a single working unit that spans angiogenic, copper-dependent collagen-synthesis, actin-remodelling and α-MSH-pathway tools. It is a frequent choice in animal-model and cell-culture research where investigators want broad coverage of repair and inflammatory pathways in parallel.\u003c\/p\u003e\n\u003cp\u003eOptic Labs supplies KLOW80 in Australia as a co-lyophilised powder, 80mg total, third-party HPLC verified at \u0026gt;99% purity for each constituent peptide. The stack is supplied strictly for laboratory research use only and is not intended for human consumption, clinical, cosmetic, diagnostic or veterinary application.\u003c\/p\u003e\n\n\u003ch2\u003eProduct specifications\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eCompound:\u003c\/strong\u003e BPC-157 (10mg) + GHK-Cu (50mg) + TB-500 (10mg) + KPV (10mg) co-lyophilised stack\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBPC-157:\u003c\/strong\u003e CAS 137525-51-0, ~1419.5 g\/mol, pentadecapeptide\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGHK-Cu:\u003c\/strong\u003e CAS 49557-75-7 (peptide) \/ 89030-95-5 (copper-bound), ~340.4 g\/mol (free peptide), Gly-His-Lys with Cu\u003csup\u003e2+\u003c\/sup\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTB-500:\u003c\/strong\u003e CAS 77591-33-4, 17-amino-acid fragment of thymosin β-4\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eKPV:\u003c\/strong\u003e CAS 67727-97-3, ~342.4 g\/mol, Lys-Pro-Val tripeptide derived from α-MSH\u003csub\u003e(11–13)\u003c\/sub\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder (co-formulated)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e \u0026gt;99% by HPLC for each peptide\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAvailable size:\u003c\/strong\u003e 80mg total per vial (10mg BPC-157 + 50mg GHK-Cu + 10mg TB-500 + 10mg KPV)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e 2–8°C, protect from light. Reconstituted: 2–8°C, used within 30 days.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOrigin:\u003c\/strong\u003e Manufactured to research-grade specifications, third-party HPLC verified\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eShipping:\u003c\/strong\u003e Australia-wide domestic dispatch from Sydney, NSW\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eResearch background\u003c\/h2\u003e\n\u003cp\u003eThe four peptides in KLOW80 cover overlapping but distinct repair and inflammatory pathways. BPC-157 is characterised in published research for angiogenic, nitric-oxide and growth-factor signalling; GHK-Cu for copper-dependent collagen synthesis and gene-expression modulation; TB-500 for actin sequestration and cell migration; KPV for α-MSH-pathway anti-inflammatory effects and gut-barrier research. Combining them allows investigators to probe parallel pathway engagement in connective-tissue, dermal, gastrointestinal and inflammation models within a single working unit.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eBPC-157: tendon, ligament and gastrointestinal injury models examining VEGF\/eNOS signalling and fibroblast outgrowth.\u003c\/li\u003e\n\u003cli\u003eGHK-Cu: collagen and elastin synthesis research in dermal fibroblasts and ex-vivo skin models.\u003c\/li\u003e\n\u003cli\u003eGHK-Cu: gene-expression studies modulating antioxidant, anti-inflammatory and tissue-remodelling pathways.\u003c\/li\u003e\n\u003cli\u003eTB-500: G-actin sequestration and actin-cytoskeleton remodelling research relevant to cell migration.\u003c\/li\u003e\n\u003cli\u003eTB-500: cardiac, dermal, corneal and hair-follicle research examining endothelial and keratinocyte migration.\u003c\/li\u003e\n\u003cli\u003eKPV: α-MSH-derived tripeptide research on NF-κB modulation and pro-inflammatory cytokine attenuation in cell-culture and rodent colitis models.\u003c\/li\u003e\n\u003cli\u003eCombined-peptide protocols in models combining inflammatory and repair endpoints, where multi-pathway coverage is the design objective.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor deeper background, see our \u003ca href=\"\/blogs\/news\/bpc-157-complete-research-guide-2025\"\u003eBPC-157 complete research guide\u003c\/a\u003e, our \u003ca href=\"\/blogs\/news\/ghk-cu-australia-copper-peptide-guide\"\u003eGHK-Cu copper peptide guide\u003c\/a\u003e, our \u003ca href=\"\/blogs\/news\/tb-500-australia-thymosin-injury-research-guide\"\u003eTB-500 research guide\u003c\/a\u003e and our \u003ca href=\"\/blogs\/news\/kpv-peptide-australia-anti-inflammatory-research\"\u003eKPV anti-inflammatory research guide\u003c\/a\u003e. Researchers working with reconstitution should also reference our \u003ca href=\"\/blogs\/news\/peptide-reconstitution-calculator-guide-australia\"\u003epeptide reconstitution guide\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch2\u003eReconstitution and handling\u003c\/h2\u003e\n\u003cp\u003eKLOW80 is co-lyophilised — all four peptides dissolve together when the vial is reconstituted. Use sterile \u003ca href=\"\/products\/bac-water-3ml-10ml\"\u003ebacteriostatic water\u003c\/a\u003e. Adding 4mL of bacteriostatic water to an 80mg vial yields 20mg\/mL total peptide, which corresponds to 2.5mg\/mL BPC-157, 12.5mg\/mL GHK-Cu, 2.5mg\/mL TB-500 and 2.5mg\/mL KPV. A 5mL reconstitution gives 16mg\/mL total (2mg\/mL BPC-157, 10mg\/mL GHK-Cu, 2mg\/mL TB-500, 2mg\/mL KPV). Add diluent slowly down the side of the vial — do not inject directly onto the lyophilised cake — and allow the powder to dissolve without vigorous shaking. Reconstituted KLOW80 should be stored at 2–8°C, protected from light, and used within 30 days. For dilution maths for any working volume, see our \u003ca href=\"\/blogs\/news\/peptide-reconstitution-calculator-guide-australia\"\u003epeptide reconstitution calculator guide\u003c\/a\u003e and our \u003ca href=\"\/blogs\/news\/peptide-storage-complete-research-guide\"\u003epeptide storage guide\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch2\u003eCommonly stacked research peptides\u003c\/h2\u003e\n\u003cp\u003eResearchers using KLOW80 commonly hold its constituent peptides separately for protocols requiring different ratios or single-compound arms:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/bpc-157\"\u003eBPC-157\u003c\/a\u003e — single-compound vial for protocols at non-stack ratios.\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/ghk-cu-50mg-100mg\"\u003eGHK-Cu\u003c\/a\u003e — single-compound copper-peptide vial.\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/tb-500\"\u003eTB-500\u003c\/a\u003e — single-compound thymosin β-4 fragment vial.\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/kpv-10mg\"\u003eKPV\u003c\/a\u003e — single-compound α-MSH-derived tripeptide for anti-inflammatory and gut-barrier research.\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/glow70-bpc-157-10mg-ghk-cu-50mg-tb-500-10mg\"\u003eGLOW70 stack\u003c\/a\u003e — three-compound version of KLOW80 without the KPV arm.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor broader stack-design context, see our \u003ca href=\"\/blogs\/news\/peptide-research-stacks-australia-combinations\"\u003epeptide research stacks overview\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch2\u003eFrequently asked questions\u003c\/h2\u003e\n\n\u003ch3\u003eIs KLOW80 legal in Australia?\u003c\/h3\u003e\n\u003cp\u003eNone of the constituent peptides — BPC-157, GHK-Cu, TB-500 or KPV — is an approved therapeutic good in Australia, and none is registered with the Therapeutic Goods Administration (TGA). Optic Labs supplies KLOW80 strictly for laboratory research, development and analytical use — not for human consumption, clinical or cosmetic application. For a detailed overview of how research peptides sit within the Australian regulatory framework, see our \u003ca href=\"\/blogs\/news\/are-peptides-legal-australia-tga-compliance-2025\"\u003eguide to peptide legality and TGA compliance in Australia\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eWhat is KLOW80?\u003c\/h3\u003e\n\u003cp\u003eKLOW80 is a co-lyophilised four-compound research stack containing 10mg BPC-157, 50mg GHK-Cu, 10mg TB-500 and 10mg KPV in a single vial. The four peptides are co-studied in repair, dermal, gastrointestinal and inflammation research. For background on each, see our \u003ca href=\"\/blogs\/news\/bpc-157-complete-research-guide-2025\"\u003eBPC-157\u003c\/a\u003e, \u003ca href=\"\/blogs\/news\/ghk-cu-australia-copper-peptide-guide\"\u003eGHK-Cu\u003c\/a\u003e, \u003ca href=\"\/blogs\/news\/tb-500-australia-thymosin-injury-research-guide\"\u003eTB-500\u003c\/a\u003e and \u003ca href=\"\/blogs\/news\/kpv-peptide-australia-anti-inflammatory-research\"\u003eKPV\u003c\/a\u003e guides.\u003c\/p\u003e\n\n\u003ch3\u003eHow does KLOW80 differ from GLOW70?\u003c\/h3\u003e\n\u003cp\u003eKLOW80 is essentially the GLOW70 stack with an additional 10mg of KPV added to the same vial. Researchers who want anti-inflammatory and gut-barrier pathway coverage alongside the angiogenic, copper-dependent collagen-synthesis and actin-remodelling tools of GLOW70 typically reach for KLOW80; researchers running designs without an inflammation arm typically use \u003ca href=\"\/products\/glow70-bpc-157-10mg-ghk-cu-50mg-tb-500-10mg\"\u003eGLOW70\u003c\/a\u003e instead.\u003c\/p\u003e\n\n\u003ch3\u003eHow much bacteriostatic water do I mix with a KLOW80 vial?\u003c\/h3\u003e\n\u003cp\u003eFor an 80mg vial, 4mL of \u003ca href=\"\/products\/bac-water-3ml-10ml\"\u003ebacteriostatic water\u003c\/a\u003e yields 20mg\/mL total peptide (2.5mg\/mL BPC-157, 12.5mg\/mL GHK-Cu, 2.5mg\/mL TB-500, 2.5mg\/mL KPV). 5mL gives 16mg\/mL total. See our \u003ca href=\"\/blogs\/news\/peptide-reconstitution-calculator-guide-australia\"\u003ereconstitution calculator guide\u003c\/a\u003e for worked examples at other volumes.\u003c\/p\u003e\n\n\u003ch3\u003eHow should reconstituted KLOW80 be stored?\u003c\/h3\u003e\n\u003cp\u003eReconstituted KLOW80 should be stored at 2–8°C, protected from light, and used within 30 days. Lyophilised vials are stable at 2–8°C until reconstitution. For full handling guidance, see our \u003ca href=\"\/blogs\/news\/peptide-storage-complete-research-guide\"\u003epeptide storage research guide\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eWhere does Optic Labs ship to?\u003c\/h3\u003e\n\u003cp\u003eOptic Labs ships Australia-wide from Sydney, NSW. Standard dispatch is next business day on orders received before the daily cut-off. International shipping is not currently offered.\u003c\/p\u003e\n\n\u003ch2\u003eLegal disclaimer\u003c\/h2\u003e\n\u003cp\u003eAll products on this site are supplied for \u003cstrong\u003elaboratory research, development or analytical use only\u003c\/strong\u003e. They are not for human consumption, clinical use, or any diagnostic, cosmetic or veterinary application. These products and statements have not been evaluated by the \u003cstrong\u003eTherapeutic Goods Administration (TGA)\u003c\/strong\u003e or the \u003cstrong\u003eAPVMA\u003c\/strong\u003e and are not intended to diagnose, treat, cure or prevent any disease. Optic Labs is not a \u003cstrong\u003ecompounding pharmacy\u003c\/strong\u003e or manufacturing facility as defined under the \u003cem\u003eTherapeutic Goods Act 1989\u003c\/em\u003e, and is not a registered provider of scheduled medicines or therapeutic goods.\u003c\/p\u003e","brand":"Optic Labs","offers":[{"title":"Default Title","offer_id":53360884547768,"sku":null,"price":180.99,"currency_code":"AUD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0952\/4196\/1656\/files\/klow_2e301683-3a56-4d55-8137-0d8348284b8e.png?v=1776428395","url":"https:\/\/opticlabsau.com\/products\/klow80-bpc-157-10mg-ghk-cu-50mg-tb-500-10mg-kpv-10mg","provider":"Optic Labs","version":"1.0","type":"link"}